Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;45(5):342-349.
doi: 10.1016/j.gastrohep.2021.05.015. Epub 2021 Jun 12.

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

[Article in English, Spanish]
Juan Turnes  1 , Diego Rincón  2 , José L Calleja  3 , Manuel B Delgado  4 , José M Rosales  5 , Raúl J Andrade  6 , María L Manzano  7 , Francisco J Salmerón  8 , María A López  9 , Marta Calvo  10 , Judith Gómez  11 , Esther Molina  12 , Yza Nubia Frias  3 , Roque Miguel Gálvez-Fernández  5 , Nicolau Vallejo-Senra  12 , Sara París  13 , Regina Santos de Lamadrid  13 , Antonio Olveira  14
Affiliations

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

[Article in English, Spanish]
Juan Turnes et al. Gastroenterol Hepatol. 2022 May.

Abstract

Background and objective: The emergence of highly tolerable, effective, and shorter duration direct-acting antivirals (DAAs) regimens offers the opportunity to simplify hepatitis C virus management but medical costs are unknown. Thus, we aimed to determine the direct medical costs associated with a combo-simplified strategy (one-step diagnosis and low monitoring) to manage HCV infection within an 8-week glecaprevir/pibrentasvir (GLE/PIB) regimen in clinical practice in Spain.

Patients and methods: Healthcare resources and clinical data were collected retrospectively from medical charts of 101 eligible patients at 11 hospitals. Participants were adult, treatment naïve subjects with HCV infection without cirrhosis in whom a combo-simplified strategy with GLE/PIB for 8 weeks were programmed between Apr-2018 and Nov-2018.

Results: The GLE/PIB effectiveness was 100% (CI95%: 96.2-100%) in the mITT population and 94.1% (CI95%: 87.5-97.8%) in the ITT population. Three subjects discontinued the combo-simplified strategy prematurely, none of them due to safety reasons. Five subjects reported 8 adverse events, all of mild-moderate intensity. Combo-simplified strategy mean direct costs were 754.35±103.60€ compared to 1689.42€ and 2007.89€ of a theoretical 12-week treatment with 4 or 5 monitoring visits, respectively; and 1370.95€ and 1689.42€ of a theoretical 8-week with 3 or 4 monitoring visits, respectively. Only 4.9% of the subjects used unexpected health care resources.

Conclusions: 8-week treatment with GLE/PIB combined with a combo simplified strategy in real-life offers substantial cost savings without affecting the effectiveness and safety compared to traditional approaches.

Keywords: Combo diagnosis-monitoring simplified strategy; Costes directos; Direct costs; Estrategia combinada simplificada de diagnóstico y monitorización; Evidencia en la vida real; Glecaprevir/pibrentasvir regimen; Hepatitis C; Real-world evidence; Régimen de glecaprevir/pibrentasvir.

PubMed Disclaimer